Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

It may be early, but some blazing investments have already delivered wealth-altering gains in this young year.

BTIG analyst David Larsen maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target of $85.00.

Of the 5 Love Languages: gift giving, quality time, words of affirmation, acts of service, and physical touch— which is the ...

When it comes to achieving healthy body weight, some men might look to what’s average and use that as their goal. For ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Maple Grove-based Morari Medical’s device “MOR” is a drug- and chemical-free approach for the common men’s sexual health ...

AJ Toler was taken aback by Hims’ scathing criticism of obesity in their weight-loss drug Super Bowl commercial.

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

The ad was graded as an “A” by the Kellogg students and place 9 th on AdMeter. It also made iSpot Tv’s list of the most ...

Hims is a US-based telehealth company offering online prescription medication, over-the-counter drugs, and personal care ...